Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclonal antibodies (mAbs) targeting human PD-L1, PD-1,...

Full description

Bibliographic Details
Main Authors: Darren J. Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, John Hood, Raymond Rothstein, Leslie Wetzel, Kelly McGlinchey, Grace Adjei, Amanda Watkins, LeeAnn Machiesky, Weimin Chen, John Andrews, Maria Groves, Michelle Morrow, Ross A. Stewart, Andrew Leinster, Robert W. Wilkinson, Scott A. Hammond, Nadia Luheshi, Claire Dobson, Michael Oberst
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
PD-L1
CTLA-4
immunotherapy
durvalumab
tremelimumab
murine surrogates
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2020.1857100

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2020.1857100

Similar Items